PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to small businesses. Applications closed on June 15, 2023.
From the official notice on Grants.gov, last changed July 13, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44
- Clinical trialsNot allowed
- Funded byNHGRI
- Median yearly award$393,814
- Typical project length1 year
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under PAR-21-247 were run by National Human Genome Research Institute (NHGRI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-21-247 in the NIH Guide.
Key dates
| Posted | July 12, 2021 |
|---|---|
| Deadline | June 15, 2023 |
| Archived by Grants.gov | July 21, 2023 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the money in the 7 programs behind this notice (65% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.
Funded under PAR-21-247 so far
NIH funded 6 projects under PAR-21-247 in fiscal 2022 to 2023, at 3 institutions. The median yearly award was $393,814.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Single-molecule protein sequencing by detection and identification of N-terminal amino acids | Glyphic Biotechnologies, Inc. | 2023 | $390,584 |
| Nanopores for Processing Proteins | Electronic Biosciences, Inc. | 2023 | $407,291 |
| Controlled Protein Translocation in Nanopores for Sequencing Applications | Electronic Biosciences, Inc. | 2023 | $393,486 |
| Structural profiling of native proteins using fluorosequencing, a single molecule protein sequencing technology | Erisyon Inc | 2022 | $216,909 |
| Single-molecule protein sequencing by iterative isolation and identification of N-terminal amino acids | Glyphic Biotechnologies, Inc. | 2022 | $409,295 |
| Dual Reader Protein Sequencing | Electronic Biosciences, Inc. | 2022 | $394,141 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Other programs behind this notice
- Cancer Cause and Prevention Research
- Cancer Detection and Diagnosis Research
- Human Genome Research
- Cancer Control
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-21-247 still open?
No. It closed on June 15, 2023.
Who can apply for Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed)?
Closed June 15, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-21-247?
NIH RePORTER lists 6 projects funded under PAR-21-247 in fiscal 2022 to 2023, at 3 institutions. The most were at Electronic Biosciences, Inc., Glyphic Biotechnologies, Inc., Erisyon Inc.
Who has won Human Genome Research grants before?
The largest recipients over five fiscal years were The Leland Stanford Junior University, University of Washington, The Broad Institute, Inc. The program made 1,255 awards worth $2.2 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)